Valeant Pharmaceuticals

VRX-T

Analysis and Opinions about VRX-T

Signal
Opinion
Expert
BUY
BUY
December 15, 2000
Likes the generic drug space, but prefers Teva. Govts will be pressured for lower health costs.
Show full opinionHide full opinion
Likes the generic drug space, but prefers Teva. Govts will be pressured for lower health costs.
WAIT
WAIT
December 8, 2000
A favourite. If you own hold, but don't buy yet. Strong earnings growth in the past 3 years and expects it to continue
Show full opinionHide full opinion
A favourite. If you own hold, but don't buy yet. Strong earnings growth in the past 3 years and expects it to continue
DON'T BUY
DON'T BUY
December 5, 2000
Well run company and has several products in the works, but prefers spreading bio techs around
Show full opinionHide full opinion
Well run company and has several products in the works, but prefers spreading bio techs around
BUY
BUY
November 30, 2000
30% earnings growth make this reasonably priced
Show full opinionHide full opinion
30% earnings growth make this reasonably priced
DON'T BUY
DON'T BUY
A sustainable company
Good company
BUY
BUY
October 27, 2000
Strong product pipeline. Good management
Show full opinionHide full opinion
Strong product pipeline. Good management
BUY WEAKNESS
BUY WEAKNESS
October 10, 2000
If republicans get in, could be a problem. Be careful of bio stocks
Show full opinionHide full opinion
If republicans get in, could be a problem. Be careful of bio stocks
BUY
BUY
October 3, 2000
Downturn/Competition got approval on similar drug
Show full opinionHide full opinion
Downturn/Competition got approval on similar drug
Ted Macklin

Unlock Ratings

Price
$102.000
Owned
Unknown
Showing 706 to 714 of 714 entries